Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

2020’s Most Significant Cancer Deals

Gain insights into the oncology deals making headlines with exclusive reporting and analysis from Scrip. Explore a snapshot view of the year’s biggest oncology deals so far, in a convenient infographic and go deeper into two major cancer deals that occurred in September with your free article pack.    

Topic cancer deal-trends

Pink Sheet: 世界の薬事規制と承認審査に関するニュース, Scrip: 世界の医...

遺伝子治療の最新動向 – eBook無料ダウンロード

ますます重要性を増す遺伝子治療分野の最新情報をeBookの形でお届けします。ニュースサービスのScrip, Pink Sheet, In Vivoより、主に以下のトピックをピックアップしました。無料でダウンロードできます。ぜひご覧下さい。

Topic research deal-trends

In Vivo: 医療用医薬品・医療機器産業の経営層向けニュース

How To Obtain Effective Relief When A Global Pandemic Disrupts Your Supply Chain

The COVID-19 pandemic is disrupting global supply chains and companies need effective tools to manage the related contract disputes. Sidley Austin partner Dorothee Schramm and senior associate Katie von der Weid, both specialized in international commercial disputes, provide tips to help companies manage the situation.

Topic Coronavirus Business Strategies Deals

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Sun Finds US ‘Challenging’

Sun Pharma’s Indian domestic operations posted strong sales in the third quarter, but this was not enough to prevent the company from reporting a 26% tumble in consolidated net profit in the face of a “challenging” US generics market and slow approvals for complex products.

Topic deal-trends

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Coherus Is Confident After US Ranibizumab Filing

Having seen its development partner Bioeq file with the FDA in December last year, Coherus is confident that it will be a leader in the US biosimilar ranibizumab market targeting Lucentis.

Topic Biosimilars Deal trends

Scrip: 世界の医療用医薬品＆製薬産業に関するニュース

Korea 2020 Outlook: Hopes Of Turnaround Amid Potential Deals, Biosimilar Launches, Biologics Law

After a year full of disappointing and unexpected events, the South Korean pharma sector is hoping for a turnaround in 2020, with expected biosimilar launches in global markets, progress in drug pipelines, large IPOs and implementation of a new law on cutting-edge biologics.

Topic clinical-trials deal-trends

Generics Bulletin: ジェネリック＆バイオシミラーニュース

Biocon Biologics Gets True North Investment

Private equity group True North continues to back the Biocon group and is picking up a minority stake in Biocon Biologics in a deal that values the subsidiary at $3bn. Separately, another subsidiary, Biocon Biosphere, has also been set up as part of efforts to unlock the full potential of the business.

Topic deal-trends strategy